Denovium

What Denovium does

Absci is a publicly traded generative AI drug creation company (NASDAQ: ABSI) that designs and optimizes biologic drug candidates — primarily monoclonal antibodies — through an integrated platform combining proprietary wet lab biology with iterative AI model cycles. Its core technology stack includes Origin-1 (a generative AI platform for de novo antibody design against zero-prior epitopes, comprising AbsciGen and AbsciBind engines), SoluPro (synthetic biology producing billions of cells), ACE Assay (high-throughput screening at greater than 4,000x traditional throughput), and a Reverse Immunology approach for AI-enabled target discovery. The company operates a 77,000+ square foot wet laboratory that generates proprietary biological training data, with research and engineering operations in Vancouver, Washington (headquarters), New York (AI Research Lab), Zug (Switzerland), and Belgrade (Serbia).

Absci monetizes through two primary revenue streams: drug creation partnerships with pharmaceutical and biotechnology companies (including AstraZeneca, Merck, Almirall, PrecisionLife, Owkin, Invetx, and Memorial Sloan Kettering) and licensing/royalty upside from its internal pipeline of clinical and preclinical candidates. The lead internal asset, ABS-201 (an anti-prolactin receptor antibody for androgenetic alopecia), entered Phase 1/2a clinical trials in December 2025, with interim data anticipated in H2 2026; the program is also being advanced into endometriosis. ABS-202 remains in candidate stage for immunology indications. The company also pursues funded research collaborations such as a Bill & Melinda Gates Foundation–backed HIV vaccine program with Caltech, and technology partnerships with NVIDIA, AMD, and Twist Bioscience for compute and synthesis infrastructure. Customer acquisition is conducted exclusively through direct enterprise business development; no self-service or consumer channel exists. Pricing is not publicly disclosed, consistent with bespoke partnership agreements.

Name

Denovium

Legal name

Absci Corporation

Website

https://denovium.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Absci is a publicly traded generative AI drug creation company that designs and optimizes monoclonal antibodies through an integrated platform combining proprietary wet lab biology with iterative AI model cycles, serving pharmaceutical partners via drug creation partnerships and advancing its own clinical pipeline.

Ownership category

akta.pro rank

Product category

AI Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design Services (541512)

SIC

Services-Prepackaged Software (7372), Services-Medical Laboratories (8071)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Generative AI drug discovery
• De novo antibody design
• Biologics development platform
• AI antibody engineering
• Computational drug creation

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Drug Creation Partnerships: Collaborative partnerships with pharmaceutical companies where Absci applies its AI platform to design differentiated biologics against challenging targets. Partners include AstraZeneca, Merck, and Almirall.
2. Internal Pipeline Development: Developing internal biologics pipeline of potential first and best-in-class assets (ABS-201, ABS-202) ready for partnering or advancement through clinical stages.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Absci operates an Integrated AI Drug Creation Platform that combines proprietary generative AI models (including Origin-1) with a 77,000+ sq ft wet laboratory in iterative cycles to design and optimize biologic drug candidates, primarily monoclonal antibodies. The company monetizes this platform through drug creation partnerships with pharmaceutical companies and through an internal pipeline of clinical-stage assets (e.g., ABS-201).

Product overview

Absci is a generative AI drug creation company operating an Integrated Drug Creation Platform that combines a 77,000+ sq ft wet lab with iterative AI model cycles. The platform leverages proprietary technologies including SoluPro (synthetic biology) and the ACE Assay (high-throughput screening at >4,000x traditional throughput) for data generation and validation. Key products include Origin-1 (generative AI for de novo antibody design against zero-prior epitopes), AI Target Discovery via Reverse Immunology, and clinical candidates ABS-201 for androgenetic alopecia and ABS-201 for endometriosis. The company serves pharmaceutical partners including AstraZeneca, Merck, and Almirall.

Differentiator

Problem solved

Functional benefit

Brands

• Origin-1: A generative AI platform that designs full-length monoclonal antibodies (mAbs) against 'zero-prior' epitopes. It delivers specific, developable binders in fewer than one hundred designs per target.
• ABS-201
• ABS-202
• Integrated Drug Creation Platform
• ACE Assay
• SoluPro
• Reverse Immunology

Products and services

• Integrated Drug Creation Platform

Quantifiable outcome

• <100 designs per target needed to deliver specific, developable binders
• +7 more outcomes

Named customers9 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• AstraZenecacoreStrategic or Co-development PartnerCollaboration using Absci's de novo AI antibody creation platform to design a potential new antibody therapy in oncology. Puja Spara, PhD, SVP of Biologics Engineering & Oncology Targeted Delivery at AstraZeneca, noted this as an exciting opportunity for novel antibody design.
• MerckcoreStrategic or Co-development PartnerMerck Global Health Innovation Fund invested in Absci as part of 'Next Horizon' technologies with potential to disrupt the biopharmaceutical industry. Prem Tumkosit, Managing Director, noted Absci's technologies may enable discovery and development that could impact human health.
• AlmirallcoreStrategic or Co-development PartnerAlmirall chose Absci for its de novo platform's ability to bring truly novel innovation to the industry's most challenging targets with high unmet medical need. Karl Ziegelbauer, PhD, EVP of R&D and CSO, noted the platform's innovation for challenging targets.
• California Institute of Technology (Caltech)coreStrategic or Co-development PartnerBill & Melinda Gates Foundation grant to Caltech bringing together state-of-the-art biotech and research expertise in immunology, protein design, and generative AI. Absci's role is to design the antibody or antibody-like protein to bind to HIV conserved sites. Part of ambitious goal to create a better, more accessible HIV therapeutic vaccination.
• NVIDIAcoreTechnology or IntegrationNVIDIA partnering to help power and scale Absci's in silico technologies. Kimberly Powell, VP of Healthcare, noted Absci's powerful data generation and AI protein engineering platform is helping the drug discovery industry, and NVIDIA is excited to help accelerate breakthroughs.
• PrecisionLifeminorStrategic or Co-development PartnerPartnership demonstrating transformational innovation potential of coupling leading generative AI approaches with PrecisionLife's unique disease biology insights. Steve Gardner, PhD, CEO & Co-founder, highlighted the combined innovation potential.
• OwkinminorStrategic or Co-development PartnerPartnership bringing together Owkin's AI agents that can identify and experimentally validate novel therapeutic targets with Absci's pioneering capabilities in developing biologic drug candidates. Thomas Clozel, MD, CEO, noted this as a significant step forward in bringing transformative therapies to patients.
• InvetxminorStrategic or Co-development PartnerInvetx selected Absci for collaboration because of their leading platform for generative AI design of human antibodies. Together they aim to build a scalable platform for bringing innovative specialty therapeutics for companion animals to market. Juergen Horn, President, noted the opportunity for scaling specialty therapeutics.
• Memorial Sloan Kettering Cancer CenterminorStrategic or Co-development PartnerAcademic partnership in the track record of partnerships supporting Absci's pipeline development and research initiatives.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Atomwise: AI-driven small molecule drug discovery company with extensive pharma partnerships. Comparable as an AI-first drug discovery partner; overlapping business model but focused on small molecules rather than biologics.
• Cradle Bio: Generative AI platform for protein engineering serving biotech and pharma partners. Comparable in generative AI for biologics, though primarily focused on protein optimization across industrial and therapeutic applications.

Direct peers

• Iambic Therapeutics: AI-driven drug discovery company combining foundation models with automated chemistry for therapeutic design. Comparable as an AI-first platform pursuing both partnership and internal pipeline economics in small molecules and biologics.
• Isomorphic Labs: Alphabet-backed AI drug discovery company applying DeepMind's protein structure prediction (AlphaFold) to therapeutic discovery. Directly comparable in generative AI for biologics/small molecules with deep-tech compute resources.
• Schrödinger: Public computational drug discovery company combining physics-based modeling with machine learning for molecular design, with both a software/services business and internal pipeline. Comparable as an AI-first drug creation platform serving pharma partners.
• Insitro: Private AI-driven drug discovery company combining ML with high-throughput biology to discover therapeutics, with major pharma partnerships. Closely comparable in operating model: integrated wet-lab + AI platform targeting pharma collaborations and internal pipeline.
• BigHat Biosciences: AI/ML-driven antibody design company combining generative models with high-throughput wet-lab validation. Closely comparable to Absci's Origin-1 capability set: de novo antibody design with integrated experimental feedback loops.
• Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput wet-lab experimentation with machine learning to discover therapeutics. Directly comparable as a fellow publicly traded, integrated AI+lab platform pursuing both partnership and internal pipeline strategies.

Broad incumbents

• Ginkgo Bioworks: Public synthetic biology platform company with cell engineering and biologics capabilities at scale. Adjacent peer in synthetic biology infrastructure (related to Absci's SoluPro) and broader cell-based R&D services for pharma.
• Benchling: Leading life sciences R&D software platform serving biotech and pharma with informatics, ELN, and data management. Adjacent in biotech software infrastructure rather than direct therapeutic competition; serves many of the same pharma customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/denovium
• YouTubeyoutube.com/c/absci
• LinkedInlinkedin.com/company/absci

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Denovium